Veru (VERU) Total Liabilities (2010 - 2026)
Veru (VERU) posted quarterly Total Liabilities of $8.3 million for Q1 2026, down 28.63% year-over-year from $11.6 million in Q1 2025, and down 20.55% quarter-over-quarter from $10.4 million in Q4 2025.
Veru (VERU) Total Liabilities (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Total Liabilities for 17 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 28.63% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (down 28.63% YoY), while the FY2025 annual figure was $11.5 million, down 59.07% from the prior year.
- Total Liabilities retreated to $8.3 million in Q1 2026 per VERU's latest filing, from $10.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $52.6 million in Q3 2022 and bottomed at $8.3 million in Q1 2026.
- Historically, Total Liabilities has averaged $28.3 million across 5 years, with a median of $28.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 115.57% — and 2025, when it slumped 59.07%.
- Veru's Total Liabilities stood at $52.1 million in 2022, then slumped by 44.39% to $29.0 million in 2023, then tumbled by 54.42% to $13.2 million in 2024, then dropped by 20.9% to $10.4 million in 2025, then decreased by 20.55% to $8.3 million in 2026.
- Business Quant data shows VERU's Total Liabilities at $8.3 million in Q1 2026, $10.4 million in Q4 2025, and $11.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Veru | 59.70 Mn | 33.91 Mn | - | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.65 Mn |
| Mar 31, 2026 | 8.30 Mn |
| Dec 31, 2025 | 10.44 Mn |
| Sep 30, 2025 | 11.50 Mn |
| Jun 30, 2025 | 11.99 Mn |
| Mar 31, 2025 | 11.62 Mn |
| Dec 31, 2024 | 13.20 Mn |
| Sep 30, 2024 | 28.10 Mn |
| Jun 30, 2024 | 27.01 Mn |
| Mar 31, 2024 | 26.59 Mn |
| Dec 31, 2023 | 28.96 Mn |
| Sep 30, 2023 | 30.34 Mn |
| Jun 30, 2023 | 39.56 Mn |
| Mar 31, 2023 | 48.53 Mn |
| Dec 31, 2022 | 52.08 Mn |
| Sep 30, 2022 | 52.56 Mn |
| Jun 30, 2022 | 43.71 Mn |
| Mar 31, 2022 | 36.83 Mn |
| Dec 31, 2021 | 24.16 Mn |
| Sep 30, 2021 | 25.85 Mn |